EPSILOGEN
Epsilogen, a global leader in the development of immunoglobulin E (IgE) antibodies to treat cancer, today announces that the Clinical Trial Application for the Phase Ib trial of MOv18 IgE has been approved by the UK Medicines and Healthcare products Regulatory Agency (MHRA).
The Phase Ib study is expected to initiate later in 2024 and will evaluate the efficacy of MOv18 IgE in patients with platinum-resistant ovarian cancer (PROC).
Dr Tim Wilson, Chief Executive Officer of Epsilogen, said: “This CTA is another significant milestone for Epsilogen and the clinical development of MOv18 IgE. We look forward to progressing MOv18 IgE into a Phase Ib efficacy study later this year as we continue to demonstrate the potential of IgE antibodies as a new, differentiated class of cancer treatments.”
About MOv18 IgE
MOv18 IgE is an immunoglobulin E (IgE) antibody targeting the folate receptor alpha (FR alpha) antigen. FR alpha is present on a variety of cancers including ovarian, endometrial, lung and triple negative breast cancer. Epsilogen has successfully completed a Phase I safety study of MOv18 IgE in PROC patients. The results of the study, published in Nature Communications, found MOv18 IgE to be safe and well tolerated, with evidence of anti-tumour activity observed. Epsilogen, alongside its partner Lonza, also announced the successful completion of large-scale Good Manufacturing Practice (GMP) manufacturing of MOv18 IgE earlier this year.
About the Phase Ib study
The Phase Ib study is designed to confirm the safety and tolerability of MOv18 IgE and demonstrate efficacy in PROC. Following the dose escalation, an expansion cohort will be recruited to make a preliminary assessment of the anti-tumour activity of MOv18 IgE at a selected dose. In addition, delay to disease progression will be assessed along with a number of translational elements to generate further understanding of MOv18 IgE in the study population.
About Epsilogen Ltd
Epsilogen is a global leader in the development of immunoglobulin E (IgE) antibodies to treat cancer. IgE’s natural function is to provide immunological defence against certain parasites. This functionality makes it an ideal treatment of solid tumours due to its strong potency, enhanced tumour access and long tissue half-life.
Epsilogen’s lead product candidate, MOv18 IgE, is the first therapeutic IgE antibody to enter the clinic and encouraging data from a completed Phase I trial demonstrated MOv18 IgE to be safe and well tolerated with early signs of clinical activity. Epsilogen has recently successfully completed large scale GMP manufacture of MOv18 IgE (the first time this has been achieved for an IgE antibody) and will initiate a Phase Ib trial in platinum-resistant ovarian cancer patients later this year. The company is also developing a pipeline of IgE therapies in oncology as well as proprietary platforms including IgE bispecifics and unique IgE/IgG combination antibody molecules (IgEGs) with enhanced functionality.
Epsilogen began operations in 2017 as a spin-out of King’s College London and has attracted venture capital financing from Epidarex Capital, Novartis Venture Fund, 3B Future Health, British Patient Capital, ALSA Ventures and Schroders Capital amongst others. Find out more at epsilogen.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240707808760/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Sharjah Hosts Inclusion International 18th World Congress 2025 ‘We Are Inclusion’ for the First Time, With 600 Participants From 74 Countries19.9.2025 19:07:00 CEST | Press release
Sharjah hosted the 18th edition of the World Congress 2025 “We Are Inclusion” for the first time in the Middle East and North Africa, under the patronage and in the presence of His Highness Sheikh Dr. Sultan bin Mohammed Al Qasimi, Supreme Council Member and Ruler of Sharjah. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250919788186/en/ Honorary Lifetime Membership certificate awarded to Sheikha Jameela bint Mohammed Al Qasimi by Inclusion International (Photo: AETOSWire) The event was held from September 15 - 17 at Expo Centre Sharjah, and organised by the Sharjah City for Humanitarian Services (SCHS) and Inclusion International, with support from the strategic partnership of the Sharjah Government Media Bureau. The congress brought together 152 speakers, including self-advocates, families, experts, and policymakers from 160 organisations across 74 countries, featuring 59 sessions, with 600 participants. During the event,
Estithmar Holding’s Listing on FTSE Mid Cap Index is Effective19.9.2025 17:02:00 CEST | Press release
As of September 18, The Qatar based Estithmar Holding Q.P.S.C. has been included in the FTSE Mid Cap Index following the September 2025 FTSE Global Equity Index Series (GEIS) Semi-Annual Review. Changes will be effective as of COB 18 Sep 2025.This inclusion reflects Estithmar Holding’s growing footprint in both regional and global markets, further strengthening its visibility among international investors and underlining its position as one of the region’s leading diversified public companies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250919701856/en/ Estithmar Holding’s Listing on FTSE Mid Cap Index is Effective (Photo: AETOSWire) The FTSE Russell index is widely tracked by international institutional investors and asset managers, and Estithmar Holding’s inclusion is expected to broaden its investor base globally, resulting in significant investment flows. The move also contributes to improving the financial attractive
LambdaTest Leads with First-to-Market Support for iPhone 17 Series on Real Devices19.9.2025 17:00:00 CEST | Press release
With iPhone 17 Series Testing Now Live, LambdaTest Boosts Developer Productivity and Streamlines Mobile App Testing Processes LambdaTest, the GenAI-native quality engineering platform, has announced the immediate availability of the iPhone 17 Series, including the iPhone 17, iPhone 17 Pro, iPhone 17 Pro Max, and the iPhone Air, on its Real Devices Platform, just hours after the official launch of Apple’s latest lineup. The addition of the iPhone 17 series further enhances LambdaTest’s already robust real device cloud, which spans thousands of iOS and Android devices. This expansion enables comprehensive cross-device and cross-OS testing at scale, ensuring developers can thoroughly test their mobile apps across a diverse range of real-world environments. “Once again, we’re the first to offer the latest iPhone models for real device testing,” said Asad Khan, CEO and Co-Founder of LambdaTest. “This launch is a testament to our commitment to providing the most up-to-date testing solutions
World-renowned Blood Transfusion Congress to Be Held in Yokohama in 202819.9.2025 17:00:00 CEST | Press release
The 2028 International Congress of the International Society of Blood Transfusion (ISBT 2028) will be held in Yokohama from June 4 to June 8, 2028. Organized collaboratively by ISBT and The Japan Society of Transfusion Medicine and Cell Therapy (JSTMCT), this marks the event’s return to Japan after 19 years, following three previous international (1960, 1996) and regional congresses (2009) held in the country. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250919907189/en/ YOKOHAMA JAPAN'S FIRST PORT OF CALL Working in partnership with the City of Yokohama and the Japan National Tourism Organization (JNTO), the Yokohama City Visitors Bureau (YCVB) and PACIFICO Yokohama supported JSTMCT’s successful bid to host ISBT 2028. The decision is testament to Japan’s advanced research capabilities, Yokohama’s convenient access and robust support infrastructure, and PACIFICO Yokohama’s outstanding reputation for hosting international c
OCP Announces Date of Second Quarter and First Half 2025 Earnings19.9.2025 14:30:00 CEST | Press release
OCP S.A. (“OCP” or the “Company”), a global leader in the fertilizer industry, will release its second quarter and first half 2025 results on Friday, September 26, 2025. The results will be available to holders of the Company’s bonds, qualified institutional buyers, securities analysts and market makers on the OCP Intralinks portal from 11:00 a.m. EDT, 4:00 p.m. Morocco and London time (GMT+1). OCP senior management will host a conference call to discuss second quarter and first half 2025 results at 12:00 p.m. EDT, 5:00 p.m. Morocco and London time (GMT+1) on Friday, September 26, 2025, for holders of the Company’s bonds, qualified institutional buyers, securities analysts and market makers. Eligible parties that have not already registered for access to the Intralinks portal may do so by contacting the Investor Relations Department by emailing g.laraki@ocpgroup.ma. About OCP OCP is a global leader in the fertilizer industry, backed by almost a century’s production history. OCP has exc
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom